- Parties: The applicant was Boehringer Ingelheim Ltd. The respondents were the Attorney General of Canada, the Minister of Health, and Jamp Pharma Corporation.

- Subject Matter: This judicial review application sought to quash the health minister’s decision granting JAMP Pharma Corporation a notice of compliance for JAMP Nintedanib 150 mg nintedanib capsules. The applicant alleged that the minister erred in law and failed to consider how the issuance of the notice of compliance impacted patient safety. This case is ongoing.

- Date: The hearing was set on Apr. 5, 2024.

- Venue: This was a federal case before the Federal Court.

- Amount: No financial award was specified.